EyePoint (EYPT) Income from Non-Controlling Interests (2020 - 2022)
EyePoint (EYPT) reported Income from Non-Controlling Interests of $1000.0 for Q4 2022, down 83.33% on a YoY basis from $6000.0 in Q4 2021, and down 50.0% sequentially from $2000.0 in Q3 2022.
EyePoint (EYPT) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
EyePoint (EYPT) has 3 years of Income from Non-Controlling Interests data on file, last reported at $1000.0 in Q4 2022.
- For the quarter ending Q4 2022, Income from Non-Controlling Interests fell 83.33% year-over-year to $1000.0; the trailing twelve-month figure through Dec 2022 stood at $12000.0 (down 47.83% YoY), and the FY2022 full-year result was $12000.0, down 47.83% from the prior year.
- Income from Non-Controlling Interests slipped to $1000.0 in Q4 2022, from $2000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $7000.0 in Q3 2021 to a low of $1000.0 in Q4 2022.
- A 3-year average of $3666.7 and a median of $3500.0 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests jumped 250.0% in 2021 and plunged 83.33% in 2022, its largest moves.
- Tracing EYPT's Income from Non-Controlling Interests over 3 years: stood at $2000.0 in 2020, then surged by 200.0% to $6000.0 in 2021, then sank by 83.33% to $1000.0 in 2022.
- Business Quant data shows EYPT's Income from Non-Controlling Interests at $1000.0 in Q4 2022, $2000.0 in Q3 2022, and $4000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | EyePoint | 1.06 Mn | -221.48 Mn | 168,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 5,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 4,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Mar 31, 2020 | 3,000.00 |